Illumina

Access to rapid, reproducible and accurate NGS kitted assays are important as many laboratories navigate the FDA / LDT Final Rule and are required to provide faster NGS results to treating clinicians.

Join Drs. Kyle C. Strickland and Rebecca A. Previs from Labcorp Oncology’s Medical Affairs team for this webinar to hear about tissue stewardship from a pathologist and oncologist’s perspectives.

In this webinar, Dr Federico Cappuzzo will speak about clinical implications of liquid biopsy-based CGP for lung cancer patients, discussing current clinical evidence and sharing his vision on future applications.

Join Illumina for an educational webinar on the new EU IVD Regulation.

This virtual interactive case-based expert forum will be discussing NTRK fusion detection and therapeutic management of NTRK fusion driven advanced cancers.

Clinical trials are increasingly using liquid biopsy samples to complement or as an alternative to invasive tissue sample collections.

Recent developments in cancer research, and rapidly increasing options for personalized therapeutics, showed the need for a comprehensive, fast and robust way to analyze the genetic information of DNA and RNA variants.

In this webinar, Albrecht Stenzinger will discuss the principles of using nextgeneration sequencing (NGS) to identify the number of genetic alterations in a tumor.